The Intelligent Revolution From Vacuum Assistance To AI‑Guided Navigation
May 12, 2026
Breast biopsy needle technology is undergoing a profound transformation from conventional puncture to intelligence and precision. The widespread adoption of Vacuum‑Assisted Biopsy (VAB) and the introduction of artificial‑intelligence (AI) navigation systems are redefining the standards for minimally invasive breast diagnosis.
Breakthroughs in Vacuum‑Assisted Biopsy (VAB) Technology
Vacuum‑assisted biopsy devices extract tissue via negative‑pressure suction, minimizing cellular damage caused by mechanical cutting. Compared with traditional core‑needle biopsy, VAB systems procure larger, more intact tissue samples, with a single sample weight exceeding 20 mg and a cellular degeneration rate below 5%. Studies in 2025 demonstrate that VAB delivers outstanding diagnostic performance in active surveillance for Low‑Risk Ductal Carcinoma in Situ with Atypical Hyperplasia (LR‑DCIS), achieving a sensitivity of 95.28% and a specificity of 100%. For suspicious microcalcifications in women under 40 years of age, the malignant detection rate of VAB (16.1%) is markedly lower than that in women over 50 years of age (20.8%), and B3 lesions are rare in this population.
Clinical Application of AI‑Guided Navigation Systems
The development and validation of a real‑time AI navigation system based on YOLOv11 for vacuum‑assisted breast biopsy mark the entry of biopsy technology into the intelligent era. Trained and validated on 22 278 ultrasound images, the system outperforms junior physicians significantly in tumor detection (mAP50 = 0.907) and needle trajectory localization (mAP50 = 0.671), and delivers real‑time processing at 1.2 ms per frame on a GPU platform. This technological breakthrough addresses the heavy reliance on intraoperative ultrasound guidance and the difficulty of lesion localization for novice operators in VABB procedures. As the first dedicated navigation tool for VABB surgery, it carries important clinical implications for shortening the learning curve and improving procedural accuracy.
Multimodal Image Fusion Technology
Deep integration of ultrasound, CT, MRI and other imaging modalities enables "three‑dimensional visualized puncture". A domestic biopsy needle system overlays preoperative CT images with intraoperative ultrasound in real time using AI algorithms, automatically marking lesion positions with an error margin within 0.5 mm. In lung biopsy procedures, this technology raises the sampling success rate for peripheral lesions to over 95%. The combination of electromagnetic navigation and robotic‑assisted technology allows robotic bronchoscopy platforms (e.g., the ION system) to be equipped with flexible puncture needles, enabling precise access to peripheral lung lesions via electromagnetic guidance.
Structural Optimization and Intelligent Design
The new‑generation biopsy needles feature multiple structural innovations. Integrated vacuum‑assisted and coaxial technologies allow multiple tissue acquisitions through a single puncture, avoiding trauma from repeated insertion. Intelligent pressure‑feedback systems incorporate pressure sensors to monitor puncture force in real time; when the needle tip approaches blood vessels or nerves, the system automatically adjusts insertion speed or triggers an alert. In animal studies, the intelligent biopsy needle reduced the risk of accidental injury to critical anatomical structures to below 2%.
Transformation of Treatment Paradigms
In March 2025, a study published in JAMA Oncology showed that for patients with HER2‑positive or triple‑negative breast cancer who achieved pathological Complete Response (pCR) confirmed by image‑guided vacuum‑assisted biopsy (VAB) after Neoadjuvant Systemic Therapy (NST), the 5‑year ipsilateral breast tumor recurrence rate was 0% among those treated with radiotherapy alone without surgery, and both 5‑year disease‑free survival and overall survival reached 100%. This study proves for the first time that radiotherapy can reliably replace surgery for carefully selected pCR patients with durable long‑term efficacy, potentially reshaping future breast cancer treatment paradigms.
